Business
Change of Adviser
Change of Adviser.
About this update from Renalytix Plc
[{"type":"text","content":"\n\n \nRenalytix plc\n(\"Renalytix\" or the \"Company\")\n \nChange of Adviser\n \nLONDON and NEW YORK, 30 August 2024 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that with the previously announced appointment of Oberon Capital (a trading name of Oberon Investments Limited) as joint broker on August 21st concurrent with Stifel Nicolaus Europe Limited (\"Stifel\"), that Investec Bank plc is ceasing to act as Joint Broker with effect from 31 August 2024. Stifel will continue to act as Nominated Adviser. \n \nFor further information, please contact:\n \n\n\n\n\nRenalytix plc\n\n\nwww.renalytix.com\n\n\n\n\nJames McCullough, CEO\n\n\nVia Walbrook PR\n\n\n\n\n\n\n\n\n\n\n\n\nStifel (Nominated Adviser and Joint Broker)\n\n\nTel: 020 7710 7600\n\n\n\n\nNicholas Moore / Nick Harland / Ben Good\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nOberon Capital (Joint Broker)\n\n\nTel: 020 3179 5300\n\n\n\n\nMike Seabrook / Nick Lovering\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nWalbrook PR Limited\n\n\nTel: 020 7933 8780 or [email protected]\n\n\n\n\nPaul McManus / Alice Woodings / Charlotte Edgar\n\n\nMob: 07980 541 893 / 07407 804 654 / 07884 664 686\n\n\n\n\n\n\n\n\n\n\n\n\nCapComm Partners\n\n\n\n\n\n\n\nPeter DeNardo\n \n\n\nTel: 415-389-6400 or [email protected]\n\n\n\n\n \nAbout Renalytix\nRenalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.\n \nImportant Notices\nStifel Nicolaus Europe Limited and Oberon Investments Limited are authorised and regulated in the United Kingdom&n...